CACNB2

(redirected from CAB2)

CACNB2

A gene on chromosome 10p12 that encodes a beta subunit of a voltage-dependent L-type calcium channel which, like other beta subunits, contributes to calcium-channel function by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation.

Molecular pathology
The gene product was first identified as an antigen target in Lambert-Eaton myasthenic syndrome, an autoimmune disorder. CACNB2 mutations are associated with Brugada symdrome, type 4.
References in periodicals archive ?
The ZNSEED obtained in RWV3006 was significantly higher than that obtained in CAB2 (37 ppm), the high FESEED check and in all other entries (Table 3).
Four entries namely, CAB2, RW547, Ndimirakaguja, and Jesca showed FESEED higher than 62.3 ppm obtained in the high FESEED check, MIB465.
All the lines except CAB2 yielded greater than 1000 kg [ha.sup.-1] while Jesca, Ndimirakaguja, UGK39, and UGK85 yielded greater than 2000 kg [ha.sup.-1] (Table 6).
Tal como relata la joven profesional del CAB "cada usuario, al final tiene su propio recorrido, su propia historia, entonces cada uno marca sus objetivos" (CAB2).
No se trabaja en base a lo ajeno, sino a lo propio, porque tambien trabajar en base a lo que la sociedad ha podido afectar a esta persona no lo se si tiene tanto sentido como trabajar en lo individual y en lo que cada uno tambien, puede tomar parte (CAB2).
Tambem semanalmente era realizada aplicacao foliar de CaB2 (2% de boro e 10% de calcio) de acordo com a recomendacao do fabricante com a finalidade de fornecer Ca e B, importantes na fase de frutificacao.
The input current is injected to the CAB2, while the output signal is taken from [I.sub.o-dw] of the CAB4.
CAB switch configuration for the first filter example [K.sub.C2k] [K.sub.R2k-1] [K.sub.R2k] CAB1 CAB2 ON ON CAB3 ON CAB4 ON [K.sub.fb] Output CAB1 CAB2 CAB3 CAB4 [I.sub.o-dw] Table 4.
Millennium is also developing, in collaboration with XOMA Ltd, MLN01, a humanized monoclonal antibody, which is being investigated for cardiovascular uses, and CAB2, a recombinant fusion protein that inhibits complement activation, currently in preclinical trials for the treatment of reperfusion injury.
Contract notice: preliminary study of development of the town center (cab2)